CompletedPhase 2NCT03180684
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Studying Vulvar intraepithelial neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inovio Pharmaceuticals
- Principal Investigator
- Jeffrey Skolnik, MDInovio Pharmaceuticals
- Intervention
- VGX-3100(biological)
- Enrollment
- 33 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2017 – 2020
Study locations (15)
- Christiana Care Health Systems, Newark, Delaware, United States
- Augusta University, Augusta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Maine Medical Center, Scarborough, Maine, United States
- University of Michigan, Ann Arbor, Michigan, United States
- St. Dominic Hospital, Jackson, Mississippi, United States
- Rutgers New Jersey, Newark, New Jersey, United States
- Columbia University Medical Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States
- Complete HealthCare for Women, Inc., Columbus, Ohio, United States
- University of Pittsburgh Medical Center - Magee Womens Hospital, Pittsburgh, Pennsylvania, United States
- Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03180684 on ClinicalTrials.gov